China’s NMPA has updated its drug approval document delivery system and published the latest list of approved medicinal products.

Key highlights:

  • Since 01-Nov-2022, individuals with administrative penalties can access and print electronic certificates via the NMPA service portal
  • Newly approved products as of 11-Nov-2025 include injections, tablets, and other formulations—such as Limonene phosphate injection and Piperacillin sodium and Tazobactam sodium for injection
  • The update lists multiple approved products across various manufacturers, supporting transparency in Regulatory activities and public health advancement
     

Consult Now

Source
https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20251111152524121.html
Select Mandate HA
NMPA
Select Mandate Function
Regulatory Affairs